Milvexian: An Oral, Bioavailable Factor XIa Inhibitor.

AXIOMATIC trials Anticoagulation Factor XI Hemostasis LIBREXIA trials Milvexian Venous thromboembolism

Journal

Cardiology and therapy
ISSN: 2193-8261
Titre abrégé: Cardiol Ther
Pays: England
ID NLM: 101634495

Informations de publication

Date de publication:
17 Aug 2024
Historique:
received: 26 05 2024
accepted: 23 07 2024
medline: 17 8 2024
pubmed: 17 8 2024
entrez: 16 8 2024
Statut: aheadofprint

Résumé

Direct oral anticoagulants have a dose-dependent increased bleeding risk which limits use in certain populations. Studies in both animals and humans with inherited variations in factor XI levels provide a theoretical basis for a drug target capable of addressing current unmet needs. Milvexian is an oral factor XIa inhibitor that has the potential to provide robust anticoagulant effect without increased bleeding compared with current standard of care. Several key studies in the preclinical, phase I, and phase II stages have reported promising safety data in venous thromboembolism and stroke prevention without compromising hemostasis. The planned phase III trials will examine the efficacy of milvexian for prevention of thrombotic events in patients with acute stroke, acute coronary syndrome, and atrial fibrillation.

Identifiants

DOI: 10.1007/s40119-024-00379-0 PMID: 39152241
pubmed: 39152241
doi: 10.1007/s40119-024-00379-0
pii: 10.1007/s40119-024-00379-0
doi:

Types de publication

Journal Article Review

Langues

eng

Informations de copyright

© 2024. The Author(s).

Références

Rymer JA, Chiswell K, Young L, et al. Analysis of oral anticoagulant dosing and adherence to therapy among patients with nonvalvular atrial fibrillation. JAMA Netw Open. 2023;6(6): e2317156. https://doi.org/10.1001/jamanetworkopen.2023.17156 .
doi: 10.1001/jamanetworkopen.2023.17156 pubmed: 37285155 pmcid: 10248740
Ballestri S, Romagnoli E, Arioli D, et al. Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review. Adv Ther. 2023;40(1):41–66. https://doi.org/10.1007/s12325-022-02333-9 .
doi: 10.1007/s12325-022-02333-9 pubmed: 36244055
Jackevicius CA, Lu L, Ghaznavi Z, Warner AL. Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2021;14(2): e007230. https://doi.org/10.1161/circoutcomes.120.007230 .
doi: 10.1161/circoutcomes.120.007230 pubmed: 33541109
Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, Seligsohn U. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost. 2011;105(2):269–73. https://doi.org/10.1160/TH10-05-0307 .
doi: 10.1160/TH10-05-0307 pubmed: 21057700
Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood. 2008;111(8):4113–7. https://doi.org/10.1182/blood-2007-10-120139 .
doi: 10.1182/blood-2007-10-120139 pubmed: 18268095
Preis M, Hirsch J, Kotler A, et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood. 2017;129(9):1210–5. https://doi.org/10.1182/blood-2016-09-742262 .
doi: 10.1182/blood-2016-09-742262 pubmed: 28039189
Meijers JCM, Tekelenburg WLH, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342(10):696–701. https://doi.org/10.1056/NEJM200003093421004 .
doi: 10.1056/NEJM200003093421004 pubmed: 10706899
Perera V, Wang Z, Luettgen J, et al. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin Transl Sci. 2022;15(2):330–42. https://doi.org/10.1111/cts.13148 .
doi: 10.1111/cts.13148 pubmed: 34558200
Harrington J, Piccini JP, Alexander JH, Granger CB, Patel MR. Clinical evaluation of factor XIa inhibitor drugs: JACC review topic of the week. J Am Coll Cardiol. 2023;81(8):771–9. https://doi.org/10.1016/j.jacc.2022.11.057 .
doi: 10.1016/j.jacc.2022.11.057 pubmed: 36813377
Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C. In vivo roles of factor XII. Blood. 2012;120(22):4296–303. https://doi.org/10.1182/blood-2012-07-292094 .
doi: 10.1182/blood-2012-07-292094 pubmed: 22993391 pmcid: 3507141
Nopp S, Kraemmer D, Ay C. Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence. Front Cardiovasc Med. 2022;9: 903029. https://doi.org/10.3389/fcvm.2022.903029 .
doi: 10.3389/fcvm.2022.903029 pubmed: 35647061 pmcid: 9133368
Grover SP, Mackman N. Intrinsic pathway of coagulation and thrombosis. Arterioscler Thromb Vasc Biol. 2019;39(3):331–8. https://doi.org/10.1161/ATVBAHA.118.312130 .
doi: 10.1161/ATVBAHA.118.312130 pubmed: 30700128
Periayah MH, Halim AS, Mat Saad AZ. Mechanism action of platelets and crucial blood coagulation pathways in hemostasis. Int J Hematol Oncol Stem Cell Res. 2017;11(4):319–27.
pubmed: 29340130 pmcid: 5767294
Reitsma SE, Pang J, Raghunathan V, et al. Role of platelets in regulating activated coagulation factor XI activity. Am J Physiol Cell Physiol. 2021;320(3):C365–74. https://doi.org/10.1152/ajpcell.00056.2020 .
doi: 10.1152/ajpcell.00056.2020 pubmed: 33471623 pmcid: 8354817
Uchiyama S, Ibayashi S, Matsumoto M, et al. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation. J Stroke Cerebrovasc Dis. 2012;21(3):165–73. https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.01.011 .
doi: 10.1016/j.jstrokecerebrovasdis.2012.01.011 pubmed: 22440950
Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. https://doi.org/10.1056/NEJMoa1107039 .
doi: 10.1056/NEJMoa1107039 pubmed: 21870978
Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84(2):527–39. https://doi.org/10.1161/01.cir.84.2.527 .
doi: 10.1161/01.cir.84.2.527
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. https://doi.org/10.1056/NEJMoa0905561 .
doi: 10.1056/NEJMoa0905561 pubmed: 19717844
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. https://doi.org/10.1056/NEJMoa1009638 .
doi: 10.1056/NEJMoa1009638 pubmed: 21830957
Fang MC, Reynolds K, Fan D, et al. Clinical outcomes of direct oral anticoagulants vs warfarin for extended treatment of venous thromboembolism. JAMA Netw Open. 2023;6(8): e2328033. https://doi.org/10.1001/jamanetworkopen.2023.28033 .
doi: 10.1001/jamanetworkopen.2023.28033 pubmed: 37581888 pmcid: 10427945
Carnicelli AP, Hong H, Connolly SJ, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145(4):242–55. https://doi.org/10.1161/CIRCULATIONAHA.121.056355 .
doi: 10.1161/CIRCULATIONAHA.121.056355 pubmed: 34985309 pmcid: 8800560
PubChem. Milvexian. https://pubchem.ncbi.nlm.nih.gov/compound/118277544 . Accessed 3 Sep 2023.
Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy. https://doi.org/10.1021/acs.jmedchem.1c00613 .
Wang X, Smith PL, Hsu MY, et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost. 2006;4(9):1982–8. https://doi.org/10.1111/j.1538-7836.2006.02093.x .
doi: 10.1111/j.1538-7836.2006.02093.x pubmed: 16961605
Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thrombosis Haemostasis. 2002;87(4):774–6.
doi: 10.1055/s-0037-1613081 pubmed: 12008966
Wang X, Cheng Q, Xu L, et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost. 2005;3(4):695–702. https://doi.org/10.1111/j.1538-7836.2005.01236.x .
doi: 10.1111/j.1538-7836.2005.01236.x pubmed: 15733058
Wang X, Li Q, Du F, Shukla N, Nawrocki AR, Chintala M. Antithrombotic effects of the novel small-molecule factor XIa inhibitor milvexian in a rabbit arteriovenous shunt model of venous thrombosis. TH Open. 2023;7(2):e97–104. https://doi.org/10.1055/a-2061-3311 .
doi: 10.1055/a-2061-3311 pubmed: 37101592 pmcid: 10125780
Small-Molecule Factor XIa Inhibitor, BMS-986177/JNJ-70033093, prevents and treats arterial thrombosis in rabbits at doses that preserve hemostasis. ISTH Congress Abstracts. https://abstracts.isth.org/abstract/small-molecule-factor-xia-inhibitor-bms-986177-jnj-70033093-prevents-and-treats-arterial-thrombosis-in-rabbits-at-doses-that-preserve-hemostasis/ . Accessed 3 Sep 2023.
Bristol-Myers Squibb. A study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of BMS-986177 in Healthy Subjects. clinicaltrials.gov; 2017. https://clinicaltrials.gov/study/NCT02608970 . Accessed 1 Sep 2023.
Janssen Research & Development, LLC. An Open-Label, Randomized, Crossover Study to Evaluate the Relative Oral Bioavailability, Pharmacokinetics, and Food Effect After Single Dose (for Part 1, Part 3, Part 4 and Part 5) or Multiple-Dose (for Part 2) Administration of JNJ-70033093 (Milvexian) in Healthy Adult Participants Using Tablet, Capsule and Dispersed Tablet Formulations. clinicaltrials.gov; 2022. Accessed September 1, 2023. https://clinicaltrials.gov/study/NCT04844424 . Accessed 1 Sep 2023.
Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021;385(23):2161–72. https://doi.org/10.1056/NEJMoa2113194 .
doi: 10.1056/NEJMoa2113194 pubmed: 34780683 pmcid: 9540352
Antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention. American College of Cardiology. Accessed September 3, 2023. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2022/08/27/04/12/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fClinical-Trials%2f2022%2f08%2f27%2f04%2f12%2fAXIOMATIC-SSP . Accessed 3 Sep 2023.
Sharma M, Molina CA, Toyoda K, et al. Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention. J Stroke Cerebrovasc Dis. 2022;31(10): 106742. https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106742 .
doi: 10.1016/j.jstrokecerebrovasdis.2022.106742 pubmed: 36037679 pmcid: 9619293
Sharma M, Molina CA, Toyoda K, et al. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2024;23(1):46–59. https://doi.org/10.1016/S1474-4422(23)00403-9 .
doi: 10.1016/S1474-4422(23)00403-9 pubmed: 38101902
Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH stroke scale using video training NINDS TPA stroke study group. Stroke. 1994;25(11):2220–6. https://doi.org/10.1161/01.str.25.11.2220 .
doi: 10.1161/01.str.25.11.2220 pubmed: 7974549
Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369(9558):283–92. https://doi.org/10.1016/S0140-6736(07)60150-0 .
doi: 10.1016/S0140-6736(07)60150-0 pubmed: 17258668
Standardized Bleeding Definitions for Cardiovascular Clinical Trials | Circulation. Accessed September 7, 2023. https://www.ahajournals.org/doi/10.1161/circulationaha.110.009449 . Accessed 7 Sep 2023.
Franco L, Becattini C, Beyer-Westendorf J, et al. Definition of major bleeding: prognostic classification. J Thromb Haemost. 2020;18(11):2852–60. https://doi.org/10.1111/jth.15048 .
doi: 10.1111/jth.15048 pubmed: 32767653
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57. https://doi.org/10.1056/NEJMoa0904327 .
doi: 10.1056/NEJMoa0904327 pubmed: 19717846
Janssen Research & Development, LLC. A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to demonstrate the efficacy and safety of Milvexian, an oral factor XIa inhibitor, for stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack. clinicaltrials.gov; 2023. Accessed September 1, 2023. https://clinicaltrials.gov/study/NCT05702034 . Accessed 1 Sep 2023.
Janssen Research & Development, LLC. A phase 3, randomized, double-blind, placebo-controlled, event-driven study to demonstrate the efficacy and safety of milvexian, an oral factor XIa inhibitor, after a recent acute coronary syndrome. clinicaltrials.gov; 2023. Accessed September 1, 2023. https://clinicaltrials.gov/study/NCT05754957 . Accessed 1 Sep 2023.
Janssen Research & Development, LLC. A phase 3, randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian, an oral factor XIa inhibitor, versus apixaban in participants with atrial fibrillation. clinicaltrials.gov; 2023. https://clinicaltrials.gov/study/NCT05757869 . Accessed 1 Sep 2023.
Campello E, Simioni P, Prandoni P, Ferri N. Clinical pharmacology of factor XI inhibitors: new therapeutic approaches for prevention of venous and arterial thrombotic disorders. J Clin Med. 2022;11(21):6314. https://doi.org/10.3390/jcm11216314 .
doi: 10.3390/jcm11216314 pubmed: 36362541 pmcid: 9654315
Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. The Lancet. 2022;399(10333):1383–90. https://doi.org/10.1016/S0140-6736(22)00456-1 .
doi: 10.1016/S0140-6736(22)00456-1
Shoamanesh A, Mundl H, Smith EE, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet. 2022;400(10357):997–1007. https://doi.org/10.1016/S0140-6736(22)01588-4 .
doi: 10.1016/S0140-6736(22)01588-4
Rao SV, Kirsch B, Bhatt DL, et al. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation. 2022;146(16):1196–206. https://doi.org/10.1161/CIRCULATIONAHA.122.061612 .
doi: 10.1161/CIRCULATIONAHA.122.061612 pubmed: 36030390
OCEANIC-AF study stopped early due to lack of efficacy. OCEANIC-AF study stopped early due to lack of efficacy. https://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-of-efficacy/ . Accessed 15 Jan 2024.
Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021;385(7):609–17. https://doi.org/10.1056/NEJMoa2105872 .
doi: 10.1056/NEJMoa2105872 pubmed: 34297496
Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA. 2020;323(2):130–9. https://doi.org/10.1001/jama.2019.20687 .
doi: 10.1001/jama.2019.20687 pubmed: 31935028 pmcid: 6990695
Lorentz CU, Tucker EI, Verbout NG, et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021;138(22):2173–84. https://doi.org/10.1182/blood.2021011725 .
doi: 10.1182/blood.2021011725 pubmed: 34086880 pmcid: 8641100
Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232–40. https://doi.org/10.1056/NEJMoa1405760 .
doi: 10.1056/NEJMoa1405760 pubmed: 25482425
Walsh M, Bethune C, Smyth A, et al. Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD. Kidney Int Rep. 2021;7(2):200–9. https://doi.org/10.1016/j.ekir.2021.11.011 .
doi: 10.1016/j.ekir.2021.11.011 pubmed: 35155859 pmcid: 8820988

Auteurs

Shyon Parsa (S)

Division of Cardiovascular Medicine, Stanford University Hospital, Stanford, CA, USA.

Sneha S Jain (SS)

Division of Cardiovascular Medicine, Stanford University Hospital, Stanford, CA, USA.

Olu Akinrimisi (O)

Division of Cardiovascular Medicine, Stanford University Hospital, Stanford, CA, USA.

Carolyn S P Lam (CSP)

National Heart Center, Singapore, Singapore.
Duke-NUS Graduate Medical School, Singapore, Singapore.
Baim Institute for Clinical Research, Boston, MA, USA.

Kenneth W Mahaffey (KW)

Duke-NUS Graduate Medical School, Singapore, Singapore. kenneth.mahaffey@stanford.edu.
Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive; Grant S-102, Stanford, CA, 94305, USA. kenneth.mahaffey@stanford.edu.

Classifications MeSH